Abstract 1378
Background
In MONARCH 3, a randomized, double-blind, phase 3 trial; continuous dosing of abemaciclib in combination with an AI (anastrozole or letrozole) conferred significant clinical benefit to postmenopausal women with HR+, HER2- ABC. We here report data from an additional 12 months of follow-up in this trial including analysis for clinically prognostic subgroups (Di Leo et al., 2018).
Methods
From the 31 October 2018 data cutoff, exploratory intermediate efficacy parameters including time to subsequent chemotherapy ([TCT] time from randomization to first chemotherapy [CT]) and time to second disease progression ([PFS2] time from randomization to discontinuation date of first post-discontinuation treatment [PDT], or starting date of the secondPDT, or death) were assessed. TCT and PFS2 were analyzed using the Kaplan-Meier method in the intent to treat (ITT) and subgroups previously identified as significantly prognostic.
Results
In the ITT population, updated PFS was 28.2 vs 14.8 months (HR [95% CI]: 0.525 [0.415, 0.665]; p<.0001) in the abemaciclib vs placebo arms, respectively. A higher number of patients discontinued the study in the placebo arm as compared to the abemaciclib arm, thereby starting a PDT. Systemic PDT was received by 178 (54%) patients in the abemaciclib arm and 123 (74.5%) in the placebo arm, of which 93 (28.4%) and 82 (49.7%) received CT respectively. Addition of abemaciclib to AI deferred the initiation of CT both in the ITT (HR [95% CI]: 0.513 [0.380, 0.691]; p<.0001) and in subgroups (Table). PFS2 was prolonged in the abemaciclib arm (HR [95% CI]: 0.637 [0.495, 0.819]; p<.0004). Consistent with the ITT population, PFS2 favored the abemaciclib arm across all subgroups of prognostic factors (Table). Safety profile was generally consistent with previously disclosed results.Table:
326P
TCT | PFS2 | |||||
---|---|---|---|---|---|---|
Abemaciclib + AI Events/N | Placebo + AI Events/N | HR (95% CI) | Abemaciclib + AI Events/N | Placebo + AI Events/N | HR (95% CI) | |
ITT | ||||||
93/328 | 82/165 | 0.513 (0.380, 0.691) | 152/328 | 106/165 | 0.637 (0.495, 0.819) | |
ECOG PS | ||||||
1 | 34/136 | 36/61 | 0.342 (0.214, 0.548) | 64/136 | 45/61 | 0.504 (0.344, 0.740) |
0 | 59/192 | 46/104 | 0.639 (0.435, 0.940) | 88/192 | 61/104 | 0.762 (0.549, 1.059) |
Bone-only disease | ||||||
Yes | 13/69 | 16/40 | 0.440 (0.211, 0.914) | 21/69 | 23/40 | 0.523 (0.289, 0.945) |
No | 80/259 | 66/125 | 0.495 (0.357, 0.686) | 131/259 | 83/125 | 0.660 (0.501, 0.871) |
Liver metastases | ||||||
Yes | 21/47 | 21/31 | 0.572 (0.313, 1.048) | 32/47 | 25/31 | 0.677 (0.401, 1.142) |
No | 72/281 | 61/134 | 0.504 (0.358, 0.709) | 120/281 | 81/134 | 0.663 (0.500, 0.881) |
Progesterone receptor status | ||||||
Positive | 66/255 | 57/128 | 0.529 (0.371, 0.753) | 115/255 | 78/128 | 0.694 (0.520, 0.927) |
Negative | 25/70 | 24/36 | 0.414 (0.236, 0.725) | 35/70 | 27/36 | 0.537 (0.325, 0.889) |
Tumor grade | ||||||
High | 22/65 | 21/32 | 0.369 (0.203, 0.672) | 27/65 | 23/32 | 0.418 (0.240, 0.730) |
Intermediate/Low | 52/179 | 48/96 | 0.512 (0.345, 0.757) | 86/179 | 63/96 | 0.671 (0.484, 0.931) |
Treatment-free interval | ||||||
<36 months | 15/44 | 18/32 | 0.465 (0.234, 0.924) | 21/44 | 24/32 | 0.506 (0.281, 0.910) |
≥36 months | 32/95 | 18/41 | 0.798 (0.448, 1.422) | 48/95 | 24/41 | 0.895 (0.548, 1.461) |
Conclusions
Addition of abemaciclib to AI prolonged PFS2 and TCT in the ITT and all prognostic subgroups.
Clinical trial identification
NCT02246621.
Editorial acknowledgement
Medical writing support was provided by Anchal Sood and editorial assistance by Rod Everhart of Syneos Health, and funded by Eli Lilly and Company.
Legal entity responsible for the study
Eli Lilly and Company.
Funding
Eli Lilly and Company.
Disclosure
M. Martín: Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Honoraria (self), Research grant / Funding (institution): Novartis; Honoraria (self): AstraZeneca; Honoraria (self): Pfizer; Honoraria (self): Eli Lilly and Company; Honoraria (self): Taiho Oncology; Honoraria (self): Pharmamar; Honoraria (self): Roche/Genentech. S. Johnston: Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Advisory / Consultancy: Eli Lilly and Company; Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Pfizer; Advisory / Consultancy, Research grant / Funding (self): Puma Biotechnology; Speaker Bureau / Expert testimony: Eisai. J. Huober: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Eli Lilly and Company; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy: Hexal; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Celgene; Honoraria (self), Advisory / Consultancy: Abbvie. A. Di Leo: Honoraria (self), Advisory / Consultancy: Amgen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Bayer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Celgene; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Eisai; Honoraria (self), Advisory / Consultancy: Genomic Health; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Eli Lilly and Company; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pierre Fabre; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Travel / Accommodation / Expenses: Daiichi Sankyo; Advisory / Consultancy: Genentech; Advisory / Consultancy: Ipsen; Advisory / Consultancy, Travel / Accommodation / Expenses: Puma Biotechnology. V.A. Andre: Shareholder / Stockholder / Stock options, Full / Part-time employment: Eli Lilly and Company. H.R. Martin: Shareholder / Stockholder / Stock options, Full / Part-time employment: Eli Lilly and Company. M.C. Hardebeck: Shareholder / Stockholder / Stock options, Full / Part-time employment: Eli Lilly and Company. M.P. Goetz: Honoraria (self): Genomic Health; Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly and Company; Advisory / Consultancy: Biovica; Advisory / Consultancy: Novartis; Advisory / Consultancy: Sermonix; Advisory / Consultancy: Context Pharm; Research grant / Funding (institution): Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
3716 - Prognostic factors for predicting early recurrence within the first year of surgery in pancreatic ductal adenocarcinoma
Presenter: Naru Kim
Session: Poster Display session 2
Resources:
Abstract
3947 - Integrated population pharmacokinetic modelling of liposomal irinotecan in patients with various tumour types, including untreated metastatic pancreatic cancer (mPC)
Presenter: Teresa Macarulla
Session: Poster Display session 2
Resources:
Abstract
2880 - Expression of long noncoding RNA and clinical outcomes of pancreatic cancer patients who received adjuvant chemotherapy by S-1 or GEM after curative resection.
Presenter: Mariko Kamiya
Session: Poster Display session 2
Resources:
Abstract
5029 - POLO: Time to treatment discontinuation and subsequent therapies following maintenance olaparib for patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC)
Presenter: Eric Van Cutsem
Session: Poster Display session 2
Resources:
Abstract
4730 - Diagnostic Value of Digital Multiplexed Detection of Single Nucleotide Variants in Pancreatic Cancer Specimens Collected by Endoscopic Ultrasound Fine-Needle Aspiration
Presenter: Irina Cazacu
Session: Poster Display session 2
Resources:
Abstract
3303 - Phase I/II study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer
Presenter: Esther Pijnappel
Session: Poster Display session 2
Resources:
Abstract
2009 - Efficacy of platinum-containing chemotherapy and prognosis of pancreatic cancer patients with homologous recombination deficiency: meta-analysis of published clinical studies
Presenter: Elizeveta Polyanskaya
Session: Poster Display session 2
Resources:
Abstract
2164 - Plasmatic CXCL8 is a marker for TGFß-activated kinase 1 (TAK1) activation which may predict resistance to nanoliposomal irinotecan (nal-IRI) in gemcitabine-refractory pancreatic cancer (PC) patients
Presenter: Valeria Merz
Session: Poster Display session 2
Resources:
Abstract
2529 - A protein level signature of four selected genes associated with survival outcomes of patients with pancreatic ductal adenocarcinoma
Presenter: Jie Hua
Session: Poster Display session 2
Resources:
Abstract
4947 - Pre-treatment serum 25-hydroxyvitamin D levels and survival in a Danish cohort of patients with pancreatic cancer
Presenter: Louise Rasmussen
Session: Poster Display session 2
Resources:
Abstract